Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Revamping the Lunesta Ad CampaignPosted: December 27, 2006Regular readers of Pharma Marketing Blog know how often I have berated Sepracor about its Lunesta ad campaign tactics. I wasn't surprised, therefore, when I read in BrandWeek that "Sepracor will 'refresh' its consumer marketing for sleep drug Lunesta in early 2007..." One question I have that readers may be able to answer: What's the market share for drugs in this category? The numbers from the BrandWeek article seem off. To read more about this, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Direct-to-Consumer Advertising Volume One 
The collection of articles and commentary in this first Pharma Marketing News Special Supplement chronicles the emerging issues of direct-to-consumer (DTC) advertising and presents pro and con opinions from experts on how DTC needs to adapt in the post-Vioxx marketing era. Topics include: DTC Pros and Cons, Straight-Talking DTC, Communicating Risk, Biotech DTC, Print DTC, and more. Order and pay for Volume One now using your credit card ONLY $29.95
If you wish to be pay by check or credit card off-line, please use: |